secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001867096-25-000017
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris exceeds FY2024 revenue guidance with $203M; Q4 positive cash flow; Recorlev up 28% sequentially
--------------------------------------------------------------------------------

- Total FY2024 revenue expected at $203M, exceeding prior guidance of $198-202M (24% YoY growth).
- Q4 2024 revenue projected at $60M (35% YoY growth); company generated positive cash flow in Q4.
- Recorlev net revenue in Q4 anticipated to increase ~$5M or 28% sequentially, with record new starts.
- Year-end cash, equivalents, and short-term investments expected to be over $71M.
- Amgen terminated XeriJect license per portfolio assessment; no material impact on Xeris outlook.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000017/0001867096-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000017/xers-20250110.htm
  HTML page:      https://secwatch.observer/filing/0001867096-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer